Editas Medicine (EDIT) Misses Q1 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Editas Medicine (EDIT) PT Lowered to $15 at Citi
May 8, 2024 4:01 PM EDTCiti analyst Samantha Semenkow lowered the price target on Editas Medicine (NASDAQ: EDIT) to $15.00 (from $16.00) while maintaining a Buy rating.
The analyst comments "On the call this morning, CSO Linda Burkly outlined Editas in vivo pipeline strategy. Editas will focus efforts on functionally... More
